Imagene AI and Sheba Medical Center have announced an expanded strategic collaboration to accelerate precision oncology through the integration of artificial intelligence (AI) and real-world clinical data.

The partnership will merge Sheba’s extensive patient datasets, including digitized pathology slides, genomic information, and longitudinal clinical records, with Imagene AI’s Cross-Modality Intelligence Engine. The goal is to enhance multimodal research, accelerate biomarker discovery, and speed the translation of insights into patient care.

Initially focused on lung cancer, where Imagene AI’s NSCLC (non-small cell lung cancer) application already delivers rapid biomarker profiling from routine biopsy images, the collaboration is now expanding into a cross-cancer platform. Sheba’s researchers will also gain access to Imagene AI’s Oncology Intelligence (OI) Suite, enabling independent analysis of complex datasets and the development of predictive models across multiple cancer types.

“Expanding our collaboration with Imagene AI empowers our pathologists and care teams to analyze multimodal data, independently develop AI applications, and move faster from hypothesis to validated signal,” said Prof. Iris Barshack, Head of the Pathology Institute at Sheba.

Imagene AI’s data infrastructure already integrates more than 3.5 million digitized pathology slides alongside diverse omics and clinical data, reinforcing its role in translational research. Dean Bitan, Co-founder and CEO of Imagene AI, emphasized that the alliance “bridges clinical evidence with cross-modality AI to derive actionable insights and bring precision oncology closer to patients.”